Dena Westphalen

Articles by Dena Westphalen

81 A First-in-Human Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients Who Have Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

ByDena Westphalen,Sarah Goldberg, MD, MPH ,Muhammad Rizwan Khawaja, MD, MPH,Jose Pacheco, MD,Jeffrey Russell,Joshua K. Sabari, MD,Jenna Zhang,Meredith Little,Kevin Moynihan,Kathleen Dorris,Mohamad Adham Salkeni

June 7th 2026

A phase 1/1b first-in-human study is evaluating the CNS-penetrant selective ERBB2 inhibitor CGT4255 across multiple tumor types, including HER2-positive breast cancer with brain metastases.

Latest Updated Articles

Trending on CancerNetwork

GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence

84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study